Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MEXATE-AQ PRESERVED vs COLUMVI
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), leading to depletion of tetrahydrofolate and inhibition of DNA synthesis, repair, and cellular replication. It also exhibits immunosuppressive and anti-inflammatory effects through inhibition of purine synthesis and modulation of cytokine release.
CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.
FDA-approved for acute lymphoblastic leukemia (ALL), meningeal leukemia, non-Hodgkin's lymphoma, mycosis fungoides, psoriatic arthritis, severe psoriasis, breast cancer, head and neck cancers, and rheumatoid arthritis. Off-label uses include ectopic pregnancy, inflammatory bowel disease, multiple sclerosis, graft-versus-host disease, and lupus nephritis.
Relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy,Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy
MEXATE-AQ PRESERVED (methotrexate) is administered intramuscularly, intravenously, or subcutaneously. For neoplastic diseases, typical adult doses range from 25-100 mg/m² weekly or 5-25 mg/m² every 6-12 hours for 2-6 doses. For rheumatoid arthritis, 7.5-20 mg once weekly. For psoriasis, 10-25 mg once weekly.
12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.
Terminal elimination half-life is 3-10 hours for low-dose therapy; at high doses, half-life increases to 8-15 hours due to saturation of renal clearance. Clinical context: Prolonged half-life in renal impairment or third-space fluid accumulation.
Terminal half-life approximately 20 days (range 14-28 days), consistent with Ig G1 monoclonal antibody clearance via intracellular catabolism.
Primarily metabolized hepatically to polyglutamated methotrexate (active form) via folylpolyglutamate synthetase; also undergoes oxidation via aldehyde oxidase. Excretion is primarily renal via glomerular filtration and active tubular secretion.
Metabolized via non-specific proteolysis into small peptides and amino acids; not metabolized by CYP450 enzymes.
Primarily renal (80-90% unchanged via glomerular filtration and active tubular secretion), with approximately 5-10% eliminated via biliary/fecal excretion. Enterohepatic recirculation occurs.
Primarily eliminated via biliary/fecal route; renal excretion is minimal (less than 1% of dose).
Approximately 50-60% bound to albumin, with binding saturable at high concentrations.
No specific protein binding data; as a monoclonal antibody, it is not bound to plasma proteins in a significant manner.
Vd is 0.4-0.8 L/kg, indicating distribution into total body water. Higher Vd (1-2 L/kg) in high-dose therapy due to tissue binding and polyglutamation.
Approximately 4.5 L (0.06 L/kg assuming 70 kg), indicating limited extravascular distribution, primarily confined to plasma and interstitial space.
Oral: 30-90% (dose-dependent, saturable absorption; lower at high doses). IM/Sub Q: 100% (complete absorption). IV: 100%.
Intravenous administration yields 100% bioavailability.
Contraindicated if creatinine clearance (Cr Cl) <10 m L/min. For Cr Cl 10-30 m L/min: reduce dose by 50%. For Cr Cl 30-60 m L/min: reduce dose by 25%. For Cr Cl >60 m L/min: no adjustment needed. Monitor renal function closely; high methotrexate doses may require additional hydration and alkalinization.
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or on dialysis.
Contraindicated in Child-Pugh class C. For Child-Pugh class B: reduce dose by 50%. For Child-Pugh class A: no dose adjustment. Avoid use in patients with significant liver disease or chronic hepatitis. Monitor liver enzymes.
No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment.
For acute lymphoblastic leukemia: induction doses of 3.3-5 mg/m² IV or IM, or higher doses per protocol (e.g., 100-1000 mg/m² IV). For juvenile idiopathic arthritis: 10-15 mg/m² once weekly (max 20-25 mg). Doses based on body surface area; adjust for renal function.
Safety and effectiveness in pediatric patients have not been established.
Elderly patients may have reduced renal function; start at low end of dose range (e.g., 5-7.5 mg weekly for rheumatoid arthritis). Monitor Cr Cl, liver function, and blood counts. Increased risk of myelosuppression and hepatotoxicity. Avoid high-dose methotrexate unless renal function confirmed adequate.
No specific dose adjustment recommended for elderly patients (≥65 years). Clinical studies included patients up to 88 years; no overall differences in safety or efficacy observed.
Methotrexate can cause severe toxicity including myelosuppression, hepatotoxicity, nephrotoxicity, pulmonary fibrosis, and severe enterocolitis. Accidental overdose has led to fatalities. It should only be prescribed by physicians experienced with antimetabolite therapy and familiar with its toxicities.
WARNING: CYTOKINE RELEASE SYNDROME (CRS). Serious or life-threatening CRS can occur, including infusion-related reactions. Premedicate and monitor during infusion. Withhold or permanently discontinue as recommended.
Monitor for bone marrow suppression, hepatotoxicity (liver function tests), renal impairment (serum creatinine), pulmonary toxicity (pneumonia-like symptoms), gastrointestinal toxicity, neurotoxicity (especially in high-dose regimens), and increased risk of infections. Avoid concomitant NSAIDs with high-dose methotrexate. Use with caution in patients with ascites, pleural effusions, or dehydration.
Cytokine release syndrome (CRS), including serious or life-threatening reactions,Neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome (ICANS),Infections, including serious and opportunistic infections,Tumor flare reaction,Embryo-fetal toxicity
Absolute: hypersensitivity to methotrexate; severe hepatic impairment; severe renal impairment (Cr Cl < 30 m L/min); severe bone marrow suppression; active infection; alcohol use disorder; pregnancy (Category X); breastfeeding. Relative: peptic ulcer disease; ulcerative colitis; obesity; diabetes.
None known.
Avoid folic acid supplements unless prescribed by your doctor for toxicity management. Caffeine may decrease methotrexate efficacy; limit intake. No specific food restrictions other than maintaining adequate hydration. Avoid grapefruit juice as it may alter methotrexate metabolism.
Avoid grapefruit and grapefruit juice. No other specific food interactions reported. Maintain adequate hydration to prevent tumor lysis syndrome.
Category X. First trimester: high risk of miscarriage, CNS and skeletal malformations. Second/third trimester: growth restriction, developmental delay.
COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. Ig G molecules cross the placenta; fetal exposure increases as pregnancy progresses, with the largest amount transferred during the third trimester. Glofitamab may cause fetal B-cell depletion and immune dysfunction. There are no adequate human data. Contraindicated during pregnancy; advise effective contraception during treatment and for 3 months after the last dose.
Contraindicated. Excreted in breast milk; M/P ratio unknown. Potential for infant toxicity.
No data on presence in human milk, effects on the breastfed child, or milk production. Human Ig G is secreted into breast milk, but minimal systemic absorption in the infant is expected. Because of potential for serious adverse reactions (including B-cell depletion), advise patients not to breastfeed during treatment and for at least 3 months after the last dose. M/P ratio: unknown.
Increased clearance in pregnancy may require dose escalation; however, contraindicated in pregnancy.
No clinical trials have evaluated dosing in pregnancy. Pharmacokinetics of therapeutic antibodies are not significantly altered by pregnancy-mediated changes; however, increased plasma volume and altered clearance may occur. No specific dose adjustments are recommended; if benefit outweighs risk, administer at standard dosing (2.5 mg and 10 mg step-up doses, then 30 mg fixed dose every 21 days for up to 12 cycles). Clinical judgment required due to lack of data; consider therapeutic drug monitoring if available.
MEXATE-AQ PRESERVED (methotrexate) is a folate analog antimetabolite. Always verify dosing route: intrathecal use requires preservative-free formulation. Ensure adequate hydration and urine alkalinization (target urine p H >7.0) to prevent methotrexate precipitation in renal tubules. Monitor CBC, LFTs, and creatinine before each dose. Leucovorin rescue is mandatory for high-dose regimens; start 24 hours after methotrexate infusion and continue until methotrexate level <0.1 µmol/L. Avoid concomitant NSAIDs and sulfonamides methotrexate toxicity.
COLUMVI (glofitamab) is a CD3x CD20 bispecific antibody for relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Administer with prior rituximab and premedication to mitigate cytokine release syndrome (CRS). Monitor for CRS closely during step-up dosing; consider tocilizumab for management. Ensure adequate IV hydration and uric acid monitoring for tumor lysis syndrome. Do not coadminister with other systemic immunosuppressants unless necessary. Assess for hepatitis B reactivation prior to initiation.
Take methotrexate exactly as prescribed; do not change dose or frequency without consulting your doctor.,Avoid alcohol completely due to increased risk of liver damage.,Drink plenty of fluids (at least 2-3 liters per day) to prevent kidney damage.,Report any signs of infection (fever, sore throat), unusual bleeding/bruising, mouth ulcers, cough, or shortness of breath immediately.,Use effective contraception during treatment and for at least 3 months after stopping (men and women).,Do not take NSAIDs (e.g., ibuprofen, naproxen) without your doctor's approval; they can increase methotrexate toxicity.,Avoid live vaccines while on treatment.,Store at room temperature, protect from light, and do not freeze.
COLUMVI is an infusion that helps your immune system attack lymphoma cells.,You will receive a low first dose and gradually higher doses to reduce side effects like fever and chills.,Common side effects include infusion reactions, tiredness, and low blood counts. Report fever, chills, or trouble breathing immediately.,Avoid grapefruit or grapefruit juice during treatment as they may affect how the medication works.,Stay well hydrated and contact your doctor if you have signs of infection or bleeding.,Do not receive live vaccines during treatment and for at least 6 months after the last dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MEXATE-AQ PRESERVED vs COLUMVI, answered by our medical review team.
MEXATE-AQ PRESERVED is a Antineoplastic Agent that works by Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), leading to depletion of tetrahydrofolate and inhibition of DNA synthesis, repair, and cellular replication. It also exhibits immunosuppressive and anti-inflammatory effects through inhibition of purine synthesis and modulation of cytokine release.. COLUMVI is a Antineoplastic Agent (Monoclonal Antibody) that works by CD20-directed cytolytic antibody; binds to CD20 antigen on B-lymphocytes, inducing antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MEXATE-AQ PRESERVED and COLUMVI depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MEXATE-AQ PRESERVED is: MEXATE-AQ PRESERVED (methotrexate) is administered intramuscularly, intravenously, or subcutaneously. For neoplastic diseases, typical adult doses range from 25-100 mg/m² weekly or 5-25 mg/m² every 6-12 hours for 2-6 doses. For rheumatoid arthritis, 7.5-20 mg once weekly. For psoriasis, 10-25 mg once weekly.. The standard adult dose of COLUMVI is: 12 mg/kg intravenously on Day 1 of each 21-day cycle for 12 cycles in combination with bendamustine. For patients with relapsed or refractory follicular lymphoma after two or more prior therapies, the recommended dose is 12 mg/kg intravenously on Day 1 of each 28-day cycle until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MEXATE-AQ PRESERVED and COLUMVI in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MEXATE-AQ PRESERVED is classified as Category C. Category X. First trimester: high risk of miscarriage, CNS and skeletal malformations. Second/third trimester: growth restriction, developmental delay.. COLUMVI is classified as Category C. COLUMVI (glofitamab) is a CD3/CD20 bispecific antibody. Based on its mechanism of action and animal studies, there is a potential for fetal harm. IgG molecules cross the placenta; . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.